心血管疾病和丸激素疗法在男性阴性过敏症
Nipun Lakshitha de Silva1,2, Bonnie Grant1, Suks Minhas3
1Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Annals of the New York Academy of Sciences
|September 7, 2024
概括
测试激素 测试激素是什么
科学领域:
- 内分泌学和心血管医学.
背景情况:
- 在心血管健康中起着复杂的作用.
- 低丸激素 (催眠症) 与心脏代谢风险因素有关.
研究的目的:
- 审查丸激素对心血管健康的生理影响.
- 为了检查男性阴高性恋症和心血管健康之间的关联.
- 为了评估丸激素治疗在低腺男性的心血管安全性.
主要方法:
- 对临床前研究,观察数据和随机对照试验的综合文献综述.
主要成果:
- 临床前数据显示,丸激素会影响多个心血管系统.
- 低丸激素与不良的代谢概况有关,但主要心血管事件的联系是不一致的.
- 丸激素治疗会增加血红素水平,但通常不会增加静脉血栓栓塞的风险.
结论:
- 丸激素治疗在中年和老年男性患有阴道腺的中期心血管安全性.
- 进一步的研究可能会澄清丸激素和心血管结果之间的复杂关系.
相关概念视频
Disorders of the Male Reproductive System
359
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
359
Testosterone: Functions and Regulation
580
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
580
Infertility in Males
255
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
255
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
136
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160


